Masaru Hirano

2.1k total citations
19 papers, 1.7k citations indexed

About

Masaru Hirano is a scholar working on Oncology, Pharmacology and Molecular Biology. According to data from OpenAlex, Masaru Hirano has authored 19 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Pharmacology and 5 papers in Molecular Biology. Recurrent topics in Masaru Hirano's work include Drug Transport and Resistance Mechanisms (10 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Masaru Hirano is often cited by papers focused on Drug Transport and Resistance Mechanisms (10 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Masaru Hirano collaborates with scholars based in Japan, United States and Switzerland. Masaru Hirano's co-authors include Yuichi Sugiyama, Yoshihisa Shitara, Kazuya Maeda, Hitoshi Sato, Hiroyuki Kusuhara, Soichiro Matsushima, Yoshitane Nozaki, Hisamitsu Hayashi, Makoto Sasaki and Hiroshi Suzuki and has published in prestigious journals such as Neurology, Journal of Pharmacology and Experimental Therapeutics and Molecular Pharmacology.

In The Last Decade

Masaru Hirano

19 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Masaru Hirano Japan 12 1.2k 734 668 301 234 19 1.7k
Marja K. Pasanen Finland 13 1.2k 1.0× 754 1.0× 577 0.9× 699 2.3× 234 1.0× 16 2.1k
Phyllissa Schmiedlin‐Ren United States 19 1.3k 1.0× 1.3k 1.7× 739 1.1× 265 0.9× 191 0.8× 31 2.5k
Robert Elsby United Kingdom 20 729 0.6× 551 0.8× 363 0.5× 224 0.7× 140 0.6× 25 1.6k
Kathryn E. Kenworthy United Kingdom 15 1.0k 0.8× 771 1.1× 557 0.8× 147 0.5× 129 0.6× 16 1.6k
Katherine S. Fenner United Kingdom 20 1.0k 0.8× 619 0.8× 483 0.7× 123 0.4× 158 0.7× 28 1.7k
Annikka Kalliokoski Finland 9 710 0.6× 423 0.6× 396 0.6× 172 0.6× 139 0.6× 12 1.2k
A. David Rodrigues United States 26 772 0.6× 924 1.3× 328 0.5× 174 0.6× 106 0.5× 49 1.8k
Cynthia Brimer United States 9 1.5k 1.2× 1.7k 2.4× 827 1.2× 308 1.0× 213 0.9× 9 3.0k
Yi‐An Bi United States 27 1.2k 0.9× 964 1.3× 554 0.8× 103 0.3× 117 0.5× 40 1.7k
Paul B. Watkins United States 15 1.0k 0.8× 956 1.3× 531 0.8× 130 0.4× 138 0.6× 20 1.7k

Countries citing papers authored by Masaru Hirano

Since Specialization
Citations

This map shows the geographic impact of Masaru Hirano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masaru Hirano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masaru Hirano more than expected).

Fields of papers citing papers by Masaru Hirano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masaru Hirano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masaru Hirano. The network helps show where Masaru Hirano may publish in the future.

Co-authorship network of co-authors of Masaru Hirano

This figure shows the co-authorship network connecting the top 25 collaborators of Masaru Hirano. A scholar is included among the top collaborators of Masaru Hirano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masaru Hirano. Masaru Hirano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Delgado, Silvia, Mitzi Williams, Morten Bagger, et al.. (2021). Comparable Ofatumumab Treatment Outcomes in Patients across Racial/Ethnic Groups in the ASCLEPIOS I/II and APOLITOS studies (4139). Neurology. 96(15_supplement). 2 indexed citations
2.
Hirano, Masaru, M. Yamada, Toshiaki Tanaka, et al.. (2021). Surveys/Research Exploring Japanese Phase I Studies in Global Drug Development: Are They Necessary Prior to Joining Global Clinical Trials?. Clinical Pharmacology in Drug Development. 10(12). 1410–1418. 3 indexed citations
3.
Rajman, Iris, et al.. (2020). New paradigm for expediting drug development in Asia. Drug Discovery Today. 25(3). 491–496. 7 indexed citations
4.
Hirano, Masaru, Parasar Pal, Tsu‐Han Lin, et al.. (2015). Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor. Clinical Pharmacokinetics. 54(7). 761–770. 6 indexed citations
5.
Daikoku, Tohru, Kazuhiro Horiba, Takashi Kawana, Masaru Hirano, & Kimíyasu Shiraki. (2013). Novel deletion in glycoprotein G forms a cluster and causes epidemiologic spread of herpes simplex virus type 2 infection. Journal of Medical Virology. 85(10). 1818–1828. 5 indexed citations
6.
Fujino, Hideki, et al.. (2011). Studies on the Interaction between Fibrates and Statins Using Human Hepatic Microsomes. Arzneimittelforschung. 53(10). 701–707. 12 indexed citations
7.
Hirano, Masaru, et al.. (2009). Relationship between Crystal Polymorphism and Solution Structure of an Imidazopyridine Derivative Developed as a Drug Substance for Osteoporosis. JOURNAL OF CHEMICAL ENGINEERING OF JAPAN. 42(3). 204–211. 6 indexed citations
8.
Hirano, Masaru, et al.. (2009). Effects of Impurities on Crystal Polymorphism of an Imidazopyridine Derivative Developed as a Drug Substance for Osteoporosis. JOURNAL OF CHEMICAL ENGINEERING OF JAPAN. 42(3). 147–152. 3 indexed citations
9.
Kato, Motohiro, Yoshihisa Shitara, Hitoshi Sato, et al.. (2008). The Quantitative Prediction of CYP-mediated Drug Interaction by Physiologically Based Pharmacokinetic Modeling. Pharmaceutical Research. 25(8). 1891–1901. 91 indexed citations
10.
Hirano, Masaru, Kazuya Maeda, Yoshihisa Shitara, & Yuichi Sugiyama. (2006). DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1. Drug Metabolism and Disposition. 34(7). 1229–1236. 251 indexed citations
11.
Tanaka, Rika, et al.. (2006). Crystallization of .BETA.-Sitosterol Using a Water-Immiscible Solvent Hexane. JOURNAL OF CHEMICAL ENGINEERING OF JAPAN. 39(8). 869–875. 21 indexed citations
12.
13.
Hirano, Masaru, Kazuya Maeda, Hisamitsu Hayashi, Hiroyuki Kusuhara, & Yuichi Sugiyama. (2005). Bile Salt Export Pump (BSEP/ABCB11) Can Transport a Nonbile Acid Substrate, Pravastatin. Journal of Pharmacology and Experimental Therapeutics. 314(2). 876–882. 125 indexed citations
14.
Hirano, Masaru, Kazuya Maeda, Soichiro Matsushima, et al.. (2005). Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin. Molecular Pharmacology. 68(3). 800–807. 212 indexed citations
15.
Hirano, Masaru, Kazuya Maeda, Yoshihisa Shitara, & Yuichi Sugiyama. (2004). Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans. Journal of Pharmacology and Experimental Therapeutics. 311(1). 139–146. 376 indexed citations
16.
17.
Shitara, Yoshihisa, Masaru Hirano, Yasuhisa Adachi, et al.. (2004). IN VITRO AND IN VIVO CORRELATION OF THE INHIBITORY EFFECT OF CYCLOSPORIN A ON THE TRANSPORTER-MEDIATED HEPATIC UPTAKE OF CERIVASTATIN IN RATS. Drug Metabolism and Disposition. 32(12). 1468–1475. 27 indexed citations
18.
Fujino, Hideki, et al.. (2003). INTERACTION BETWEEN FIBRATES AND STATINS - METABOLIC INTERACTIONS WITH GEMFIBROZIL. Drug metabolism and drug interactions. 19(3). 161–176. 19 indexed citations
19.
Fujino, Hideki, et al.. (1999). Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase. (5). In Vitro Metabolism and Plasma Protein Binding in Animals and Human.. Drug Metabolism and Pharmacokinetics. 14(6). 415–424. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marja K. Pasanen Breakdown of academic impact, for papers by Phyllissa Schmiedlin‐Ren Breakdown of academic impact, for papers by Robert Elsby Breakdown of academic impact, for papers by Kathryn E. Kenworthy Breakdown of academic impact, for papers by Katherine S. Fenner Breakdown of academic impact, for papers by Annikka Kalliokoski Breakdown of academic impact, for papers by A. David Rodrigues Breakdown of academic impact, for papers by Cynthia Brimer Breakdown of academic impact, for papers by Yi‐An Bi Breakdown of academic impact, for papers by Paul B. Watkins
Rankless by CCL
2026